文献速递骨质疏松与钙磷/甲状旁腺肥胖与代谢综合征

良性及恶性疾病中颌骨坏死与抗骨吸收药物:欧洲钙化组织学会(ECTS)组织的批判性综述

Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

欧洲钙化组织学会(ECTS)工作组对现有文献进行更新综述,评估不同骨骼疾病患者中药物相关性颌骨坏死(MRONJ)的发生率、特征和治疗。结果显示,晚期恶性肿瘤患者的MRONJ风险远高于良性骨病患者,但所有患者类别中MRONJ的总体风险远低于抗骨吸收治疗的获益。

要点

  • 晚期恶性肿瘤患者的MRONJ风险远高于良性骨病患者。
  • 风险差异与抗骨吸收药物剂量更高、给药更频繁及合并用药有关。
  • 所有患者类别中,MRONJ的总体风险远低于抗骨吸收治疗的获益。

核心结论

  • MRONJ的风险主要取决于基础骨疾病和所采用的抗骨吸收方案。
  • 医生和牙医应牢记,抗骨吸收治疗的获益远大于MRONJ发生的风险。

研究设计与样本

  • 欧洲钙化组织学会(ECTS)工作组与2名专家对现有文献进行更新详细综述,涵盖从骨质疏松到预防癌症治疗引起的骨丢失及骨转移患者骨骼相关事件的MRONJ发生率、特征和治疗。

主要发现

  • 晚期恶性肿瘤患者相比良性骨病患者MRONJ风险更高,原因包括抗骨吸收药物剂量更高、给药更频繁、一般健康状况受损以及合并使用易致MRONJ的其他药物。
  • 所有患者类别中MRONJ的总体风险显著低于抗骨吸收治疗的获益。

临床怎么用

  • 原文未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Antiresorptive therapy significantly reduces fracture risk in patients with benign bone disease and skeletal-related events (SREs) in patients with bone metastases (BM). Osteonecrosis of the jaw (ONJ) is a rare but severe condition manifested as necrotic bone lesion or lesions of the jaws. ONJ has been linked to the use of potent antiresorptive agents, termed medication-related ONJ (MRONJ). OBJECTIVE: We aimed to identify the differences various aspects of MRONJ among distinct patient categories and provide recommendations on how to mitigate the risk and optimally manage MRONJ in each of them. METHODS: A working group of the European Calcified Tissue Society (ECTS) and 2 experts performed an updated detailed review of existing literature on MRONJ incidence, characteristics, and treatment applied in bone diseases with variable severity of skeletal insult, ranging from osteoporosis to prevention of cancer treatment-induced bone loss and SREs in cancer patients with BM. RESULTS: The risk for MRONJ is much higher in patients with advanced malignancies compared to those with benign bone diseases because of the higher doses and more frequent administration of antiresorptive agents in individuals with compromised general health, along with coadministration of other medications that predispose to MRONJ. The overall risk for MRONJ is considerably lower than the benefits in all categories of patients. CONCLUSION: The risk for MRONJ largely depends on the underlying bone disease and the relevant antiresorptive regimen applied. Physicians and dentists should keep in mind that the benefits of antiresorptive therapy far outweigh the risk for MRONJ development.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Anastasilakis AD, Pepe J, Napoli N, et al. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS. J Clin Endocrinol Metab. 2022. PMID: 34922381. doi:10.1210/clinem/dgab888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。